Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Science - United States
doi 10.1111/cas.14139
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design

Future Oncology
MedicineCancer ResearchOncology
2020English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma

Investigational New Drugs
OncologyPharmacology
2020English

A Phase 1/2 Study of Evofosfamide, a Hypoxia-Activated Prodrug With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

A Phase I Clinical Study of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy